Sera Prognostics Inc (SERA)

Currency in USD
3.59
-0.01(-0.28%)
Closed·
3.590.00(0.00%)
·
SERA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.543.66
52 wk Range
1.378.73
Key Statistics
Prev. Close
3.59
Open
3.57
Day's Range
3.54-3.66
52 wk Range
1.37-8.73
Volume
27.09K
Average Volume (3m)
44.77K
1-Year Change
-58.26%
Book Value / Share
2.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SERA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.00
Upside
+39.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Sera Prognostics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Sera Prognostics Inc Company Profile

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc Earnings Call Summary for Q3/2025

  • Sera Prognostics Q3 2025 reported EPS of -$0.16, beating forecasts by 30.43%, but revenue severely missed at $16,000 vs expected $150,000, causing stock to drop 6.73% to $3.12.
  • Revenue declined from $29,000 YoY while net loss improved slightly to $7.8 million. The company maintains strong cash reserves of $102.4 million as of September 30, 2025.
  • Management remains focused on commercializing the PreTRM test and plans European market entry with regulatory submission in early 2026.
  • CEO Zhenya Lindgard expressed confidence about the imminent publication of the PRIME study results, which is expected 'in the coming weeks.'
  • The company faces ongoing revenue generation challenges despite EPS improvements, with plans to maintain similar expense levels in 2026 while expanding sales and marketing efforts.
Last Updated: 11/14/2025, 07:08 AM
Read Full Transcript

Compare SERA to Peers and Sector

Metrics to compare
SERA
Peers
Sector
Relationship
P/E Ratio
−4.2x−3.3x−0.6x
PEG Ratio
−0.170.020.00
Price/Book
1.7x1.7x2.6x
Price / LTM Sales
1,458.5x121.4x3.2x
Upside (Analyst Target)
39.3%14.5%41.8%
Fair Value Upside
Unlock−4.8%5.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.00
(+39.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy5.00+39.28%-New CoverageDec 15, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.16 / -0.23
Revenue / Forecast
16.00K / 150.00K
EPS Revisions
Last 90 days

SERA Income Statement

People Also Watch

71.59
TTMI
+0.99%
19.4900
ADMA
-1.96%
167.3400
NUTX
-6.80%
244.90
SNDK
+1.60%
275.73
PRAX
-1.67%

FAQ

What Is the Sera Prognostics (SERA) Stock Price Today?

The Sera Prognostics stock price today is 3.59

What Stock Exchange Does Sera Prognostics Trade On?

Sera Prognostics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sera Prognostics?

The stock symbol for Sera Prognostics is "SERA."

What Is the Sera Prognostics Market Cap?

As of today, Sera Prognostics market cap is 138.56M.

What Is Sera Prognostics's Earnings Per Share (TTM)?

The Sera Prognostics EPS (TTM) is -0.75.

When Is the Next Sera Prognostics Earnings Date?

Sera Prognostics will release its next earnings report on Mar 24, 2026.

From a Technical Analysis Perspective, Is SERA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sera Prognostics Stock Split?

Sera Prognostics has split 0 times.

How Many Employees Does Sera Prognostics Have?

Sera Prognostics has 64 employees.

What is the current trading status of Sera Prognostics (SERA)?

As of Dec 24, 2025, Sera Prognostics (SERA) is trading at a price of 3.59, with a previous close of 3.59. The stock has fluctuated within a day range of 3.54 to 3.66, while its 52-week range spans from 1.37 to 8.73.

What Is Sera Prognostics (SERA) Price Target According to Analysts?

The average 12-month price target for Sera Prognostics is USD5, with a high estimate of USD5 and a low estimate of USD5. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +39.28% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.